CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR THERAPY OF SEVERE CHRONIC EBV I

临床试验：自体 EBV 特异性 CTLS 用于治疗严重慢性 EBV I

• 批准号: 7950676
• 负责人: HELEN E HESLOP
• 金额: $ 0.27万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950676
• 关键词: Antiviral Agents; Autologous; Cell Line; Chronic; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cytotoxic T-Lymphocytes; EBV-Specific Cytotoxic T-Lymphocyte; Epstein-Barr Virus Infections; Funding; Generations; Grant; Individual; Injection of therapeutic agent; Institution; Pathogenesis; Patients; Protocols documentation; Research; Research Personnel; Resources; Safety; Source; Syndrome; T-Lymphocyte; United States National Institutes of Health; clinical effect; intravenous injection

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The pathogenesis of severe chronic EBV infection syndrome may relate to the presence of circulating inhibitory factors that disable the generation of EBV-specific T cells to control EBV infection and can be overcome by generating autologous EBV specific CTL ex vivo and adoptively transferring them to the recipient. SPECIFIC AIMS The specific objectives of this protocol are 1) To determine the safety of intravenous injections of autologous EBV specific cytotoxic T cell lines in individuals with severe chronic EBV infection, 2) To determine antiviral and immunological efficacy of intravenous injections of CTLs in these patients, 3) to assess the clinical effects of these injections.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 严重的慢性EBV感染综合征的发病机制可能与存在循环抑制因子的存在有关，这些抑制因子禁用EBV特异性T细胞的产生以控制EBV感染，并且可以通过产生自动ebv特异性CTL Ex Vivo来克服，并将其传递到接收方。 具体目标 该协议的具体目标是 1）确定静脉注射自体EBV特异性细胞毒性T细胞系在患有严重慢性EBV感染的个体中 2）确定这些患者静脉注射CTL的抗病毒和免疫学功效， 3）评估这些注射的临床作用。